SeaStar Medical to Become Public via Business Combination with LMF Acquisition Opportunities (LMAO)

May 3, 2022

SeaStar Medical, a developer of an extracorporeal Selective Cytopheretic Device (SCD) for treating acute kidney injury and hyperinflammation, is merging with Nasdaq-listed SPAC LMF Acquisition Opportunities, Inc. The merger (an ~$85 million SPAC transaction advised by Skyway) is intended to provide SeaStar access to capital markets to accelerate clinical development, FDA filings, and commercialization.

Buyers
LMF Acquisition Opportunities, Inc. (Nasdaq: LMAO)
Targets
SeaStar Medical, Inc.
Industry
Medical Devices
Location
Colorado, United States
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.